Regulation of human vascular protease-activated receptor-3 through mRNA stabilization and the transcription factor nuclear factor of activated T cells (NFAT)

Molecular Pharmacology

Volumn 80, Issue 2, 2011, Pages 337-344

  Rosenkranz, Anke C ^a   Rauch, Bernhard H ^a,d   Doller, Anke ^b   Eberhardt, Wolfgang ^b   Böhm, Andreas ^a   Bretschneider, Ellen ^c   Schrör, Karsten ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DACTINOMYCIN; FORSKOLIN; ILOPROST; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; PHORBOL ESTER; PROTEINASE ACTIVATED RECEPTOR 3; SMALL INTERFERING RNA; THROMBIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT 2; UNCLASSIFIED DRUG;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MYRISTYLATION; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REGULATORY MECHANISM; RNA BINDING; SMOOTH MUSCLE FIBER;

ANTIGENS, SURFACE; CELL CYCLE PROTEINS; CYCLIC AMP; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; NFATC TRANSCRIPTION FACTORS; OLIGOPEPTIDES; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 79960259343     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.072850     Document Type: Article

References (37)

1. Belton O, Byrne D, Kearney D, Leahy A, and Fitzgerald DJ (2000) Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102:840-845.
2. Borissoff JI, Spronk HM, Heeneman S, and ten Cate H (2009) Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res 82:392-403.
3. Bretschneider E, Spanbroek R, Lötzer K, Habenicht AJ, and Schrör K (2003) Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. Thromb Haemost 90:704-709. (Pubitemid 37287639)
4. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264.
5. Debey S, Meyer-Kirchrath J, and Schrör K (2003) Regulation of cyclooxygenase-2 expression by iloprost in human vascular smooth muscle cells. Role of transcription factors CREB and ICER. Biochem Pharmacol 65:979-988. (Pubitemid 36293680)
6. Doller A, Akool el-S, Huwiler A, Müller R, Radeke HH, Pfeilschifter J, and Eberhardt W (2008) Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol 28:2608-2625.
7. Fallier-Becker P, Rupp J, Fingerle JEB (1990) Smooth Muscle Cells from Rabbit Aorta, in Cell Culture Techniques in Heart and Vessel Research (Piper H ed) pp 247-270. Berlin/Heidelberg/New York: Springer Verlag.
8. Fetalvero KM, Shyu M, Nomikos AP, Chiu YF, Wagner RJ, Powell RJ, Hwa J, and Martin KA (2006) The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol 290:H1337-H1346.
9. Forrester JS, Fishbein M, Helfant R, and Fagin J (1991) A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 17:758-769.
10. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, and Coughlin SR (1997) Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386:502-506. (Pubitemid 27164077)
11. Jesmin S, Gando S, Zaedi S, and Sakuraya F (2007) Differential expression, time course and distribution of four PARs in rats with endotoxin-induced acute lung injury. Inflammation 30:14-27. (Pubitemid 46438044)
12. Klöss S, Srivastava R, and Mülsch A (2004) Down-regulation of soluble guanylyl cyclase expression by cyclic AMP is mediated by mRNA-stabilizing protein HuR. Mol Pharmacol 65:1440-1451.
13. Martorell L, Martínez-González J, Rodríguez C, Gentile M, Calvayrac O, and Badimon L (2008) Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 99:305-315. (Pubitemid 351230960)
14. McLaughlin JN, Patterson MM, and Malik AB (2007) Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci USA 104:5662-5667. (Pubitemid 47175737)
15. Misquitta CM, Iyer VR, Werstiuk ES, and Grover AK (2001) The role of 3′- untranslated region (3′-UTR) mediated mRNA stability in cardiovascular pathophysiology. Mol Cell Biochem 224:53-67. (Pubitemid 32962652)
16. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, and Coughlin SR (2000) PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404: 609-613. (Pubitemid 30205059)
17. Ofosu FA (2003) Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Transfus Apher Sci 28:265-268.
18. Ostrowska E and Reiser G (2008) The protease-activated receptor-3 (PAR-3) can signal autonomously to induce interleukin-8 release. Cell Mol Life Sci 65:970-981.
19. Pape R, Rauch BH, Rosenkranz AC, Kaber G, and Schrör K (2008) Transcriptional inhibition of protease-activated receptor-1 expression by prostacyclin in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28:534-540.
20. 2+-desensitizing mechanisms activated by forskolin and phenylephrine pretreatment, but not 8-bromo-cGMP. Am J Physiol Cell Physiol 290:C1552-C1559.
21. Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, Pape R, Fischer JW, Schrör K, and Weber AA (2005) Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 96:e1-6.
22. Rauch BH, Bretschneider E, Braun M, and Schrör K (2002) Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ Res 90:1122-1127. (Pubitemid 34627912)
23. Rosenkranz AC, Rauch BH, Freidel K, and Schrör K (2009) Regulation of protease-activated receptor-1 by vasodilatory prostaglandins via NFAT. Cardiovasc Res 83:778-784.
24. Schrör K, Bretschneider E, Fischer K, Fischer JW, Pape R, Rauch BH, Rosenkranz AC, and Weber AA (2010) Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins. Thromb Haemost 103: 884-890.
25. Sheridan CM, Heist EK, Beals CR, Crabtree GR, and Gardner P (2002) Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. J Biol Chem 277: 48664-48676. (Pubitemid 35470830)
26. Sokolova E, Grishina Z, Bühling F, Welte T, and Reiser G (2005) Protease-activated receptor-1 in human lung fibroblasts mediates a negative feedback downregulation via prostaglandin E2. Am J Physiol Lung Cell Mol Physiol 288:L793-L802. (Pubitemid 40547903)
27. Sokolova E, Hartig R, and Reiser G (2008) Downregulation of protease-activated receptor-1 in human lung fibroblasts is specifically mediated by the prostaglandin E receptor EP2 through cAMP elevation and protein kinase A. FEBS J 275:3669-3679.
28. Steinberg SF (2005) The cardiovascular actions of protease-activated receptors. Mol Pharmacol 67:2-11.
29. Subramanian VA, Hernandez Y, Tack-Goldman K, Grabowski EF, and Weksler BB (1986) Prostacyclin production by internal mammary artery as a factor in coronary artery bypass grafts. Surgery 100:376-383. (Pubitemid 16037561)
30. Trejo J (2003) Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther 307:437-442.
31. Vidwan P, Pathak A, Sheth S, Huang J, Monroe DM, and Stouffer GA (2010) Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 30:2587-2596.
32. Vouret-Craviari V, Auberger P, Pouysségur J, and Van Obberghen-Schilling E (1995) Distinct mechanisms regulate 5-HT2 and thrombin receptor desensitization. J Biol Chem 270:4813-4821.
33. Wang H, Ubl JJ, and Reiser G (2002) Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 37:53-63. (Pubitemid 34103094)
34. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, and Salam TA (1994) Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 75:1029-1038. (Pubitemid 24351448)
35. Wysoczynski M, Liu R, Kucia M, Drukala J, and Ratajczak MZ (2010) Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling. Mol Cancer Res 8:677-690.
36. Yellaturu CR, Ghosh SK, Rao RK, Jennings LK, Hassid A, and Rao GN (2002) A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. Biochem J 368:183-190. (Pubitemid 35463421)
37. Yu H, Sliedregt-Bol K, Overkleeft H, van der Marel GA, van Berkel TJ, and Biessen EA (2006) Therapeutic potential of a synthetic peptide inhibitor of nuclear factor of activated T cells as antirestenotic agent. Arterioscler Thromb Vasc Biol 26: 1531-1537.